Novel translational approaches to the search for precision therapies for acute respiratory distress syndrome

Nuala J Meyer, Carolyn S Calfee, Nuala J Meyer, Carolyn S Calfee

Abstract

In the 50 years since acute respiratory distress syndrome (ARDS) was first described, substantial progress has been made in identifying the risk factors for and the pathogenic contributors to the syndrome and in characterising the protein expression patterns in plasma and bronchoalveolar lavage fluid from patients with ARDS. Despite this effort, however, pharmacological options for ARDS remain scarce. Frequently cited reasons for this absence of specific drug therapies include the heterogeneity of patients with ARDS, the potential for a differential response to drugs, and the possibility that the wrong targets have been studied. Advances in applied biomolecular technology and bioinformatics have enabled breakthroughs for other complex traits, such as cardiovascular disease or asthma, particularly when a precision medicine paradigm, wherein a biomarker or gene expression pattern indicates a patient's likelihood of responding to a treatment, has been pursued. In this Review, we consider the biological and analytical techniques that could facilitate a precision medicine approach for ARDS.

Copyright © 2017 Elsevier Ltd. All rights reserved.

Figures

Figure 1
Figure 1
Integrative approaches to identify and test new precision therapies for acute respiratory distress syndrome Observations made from candidate and discovery methods fuel traditional hypothesis testing and inform novel designs such as EVLP or lung-on-a-chip. Drug candidates with a consistent signal for benefit across multiple study designs are the most promising for biomarker-enriched clinical trials. EVLP=ex-vivo lung perfusion. CRISPR=clustered regularly interspaced short palindromic repeats. CAS9=CRISPR-associated protein 9.
Figure 2
Figure 2
Ex-vivo lung perfusion system Human lungs under the dome are ventilated and perfused.
Figure 3
Figure 3
Illustration of a microfabricated lung-on-a-chip The chip consists of a three-dimensional microchannel system with culture chambers for both epithelium and endothelium at a porous interface. The epithelium and endothelium are capable of being stretched and perfused.

References

    1. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet. 1967;290:319–323.
    1. Network ARDS. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med. 2000;342:1301–1308.
    1. Dellinger RP, Levy MM, Rhodes A. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39:165–228.
    1. Rhodes A, Evans LE, Alhazzani W. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med. 2017;45:486–552.
    1. Ouellette DR, Patel S, Girard TD. Liberation from mechanical ventilation in critically ill adults: an official American College of Chest Physicians/American Thoracic Society clinical practice guideline: inspiratory pressure augmentation during spontaneous breathing trials, protocols minimizing sedation, and noninvasive ventilation immediately after extubation. Chest. 2017;151:166–180.
    1. Girard TD, Alhazzani W, Kress JP. An official American Thoracic Society/American College of Chest Physicians clinical practice guideline: liberation from mechanical ventilation in critically ill adults. Rehabilitation protocols, ventilator liberation protocols, and cuff leak tests. Am J Respir Crit Care Med. 2017;195:120–133.
    1. Bellani G, Laffey JG, Pham T. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315:788–800.
    1. Ranieri VM, Rubenfeld GD, Thompson BT, for the ARDS Definition Task Force Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307:2526–2533.
    1. Papazian L, Forel JM, Gacouin A. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010;363:1107–1116.
    1. Truwit JD, Bernard GR, Steingrub J, for the National Heart, Lung, and Blood Institute ARDS Clinical Trials Network Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med. 2014;370:2191–2200.
    1. McAuley DF, Laffey JG, O'Kane CM. Simvastatin in the acute respiratory distress syndrome. N Engl J Med. 2014;371:1695–1703.
    1. Smith FG, Perkins GD, Gates S, for the BALTI-2 study investigators Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial. Lancet. 2012;379:229–235.
    1. Matthay MA, Brower RG, Carson S, for the National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network Randomized, placebo-controlled clinical trial of an aerosolized β2-agonist for treatment of acute lung injury. Am J Respir Crit Care Med. 2011;184:561–568.
    1. Zeiher BG, Artigas A, Vincent JL. Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study. Crit Care Med. 2004;32:1695–1702.
    1. Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA, for the NHLBI ARDS Network Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014;2:611–620.
    1. Brenner JS, Greineder C, Shuvaev V, Muzykantov V. Endothelial nanomedicine for the treatment of pulmonary disease. Expert Opin Drug Deliv. 2015;12:239–261.
    1. Famous KR, Delucchi K, Ware LB. Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med. 2017;195:331–338.
    1. Beitler JR, Goligher EC, Schmidt M. Personalized medicine for ARDS: the 2035 research agenda. Intensive Care Med. 2016;42:756–767.
    1. Prescott HC, Calfee CS, Thompson BT, Angus DC, Liu VX. Toward smarter lumping and smarter splitting: rethinking strategies for sepsis and acute respiratory distress syndrome clinical trial design. Am J Respir Crit Care Med. 2016;194:147–155.
    1. Ranieri VM, Suter PM, Tortorella C. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. JAMA. 1999;282:54–61.
    1. Parsons PE, Eisner MD, Thompson BT. Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Crit Care Med. 2005;33:1–6.
    1. Meduri GU, Headley S, Kohler G. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest. 1995;107:1062–1073.
    1. Meduri GU, Kohler G, Headley S, Tolley E, Stentz F, Postlethwaite A. Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome. Chest. 1995;108:1303–1314.
    1. Katzenstein AL, Bloor CM, Leibow AA. Diffuse alveolar damage—the role of oxygen, shock, and related factors. A review. Am J Pathol. 1976;85:209–228.
    1. Wiener-Kronish JP, Albertine KH, Matthay MA. Differential responses of the endothelial and epithelial barriers of the lung in sheep to Escherichia coli endotoxin. J Clin Invest. 1991;88:864–875.
    1. Meyer NJ, Christie JD. Genetic heterogeneity and risk for ARDS. Semin Respir Crit Care Med. 2013;34:459–474.
    1. Meyer NJ. Beyond single-nucleotide polymorphisms: genetics, genomics, and other ‘omic approaches to acute respiratory distress syndrome’. Clin Chest Med. 2014;35:673–684.
    1. Blondonnet R, Constantin JM, Sapin V, Jabaudon M. A pathophysiologic approach to biomarkers in acute respiratory distress syndrome. Dis Markers. 2016;2016:3501373.
    1. Ware LB, Calfee CS. Biomarkers of ARDS: what's new? Intensive Care Med. 2016;42:797–799.
    1. Brown SM, Grissom CK, Rondina MT. Polymorphisms in key pulmonary inflammatory pathways and the development of acute respiratory distress syndrome. Exp Lung Res. 2015;41:155–162.
    1. Shortt K, Chaudhary S, Grigoryev D. Identification of novel single nucleotide polymorphisms associated with acute respiratory distress syndrome by Exome-Seq. PLoS One. 2014;9:e111953.
    1. Sapru A, Liu KD, Wiemels J. Association of common genetic variation in the protein C pathway genes with clinical outcomes in acute respiratory distress syndrome. Crit Care. 2016;20:151.
    1. Ghosh CC, David S, Zhang R. Gene control of tyrosine kinase TIE2 and vascular manifestations of infections. Proc Natl Acad Sci USA. 2016;113:2472–2477.
    1. Evans CR, Karnovsky A, Kovach MA, Standiford TJ, Burant CF, Stringer KA. Untargeted LC–MS metabolomics of bronchoalveolar lavage fluid differentiates acute respiratory distress syndrome from health. J Proteome Res. 2014;13:640–649.
    1. Stringer KA, Serkova NJ, Karnovsky A, Guire K, Paine R, Standiford TJ. Metabolic consequences of sepsis-induced acute lung injury revealed by plasma 1H-nuclear magnetic resonance quantitative metabolomics and computational analysis. Am J Physiol Lung Cell Mol Physiol. 2011;300:L4–11.
    1. Calfee CS, Janz DR, Bernard GR. Distinct molecular phenotypes of direct versus indirect ARDS in single-center and multicenter studies. Chest. 2015;147:1539–1548.
    1. Blondonnet R, Constantin JM, Sapin V, Jabaudon M. A pathophysiologic approach to biomarkers in acute respiratory distress syndrome. Dis Markers. 2016;2016:20.
    1. Forel JM, Guervilly C, Hraiech S. Type III procollagen is a reliable marker of ARDS-associated lung fibroproliferation. Intensive Care Med. 2015;41:1–11.
    1. Battaglia M, Atkinson MA. The streetlight effect in type 1 diabetes. Diabetes. 2015;64:1081–1090.
    1. Manolio TA, Collins FS, Cox NJ. Finding the missing heritability of complex diseases. Nature. 2009;461:747–753.
    1. Christie JD, Wurfel MM, Feng R. Genome wide association identifies PPFIA1 as a candidate gene for acute lung injury risk following major trauma. PLoS One. 2012;7:e28268.
    1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303–1310.
    1. Copeland KT, Checkoway H, McMichael AJ, Holbrook RH. Bias due to misclassification in the estimation of relative risk. Am J Epidemiol. 1977;105:488–495.
    1. Tejera P, Meyer NJ, Chen F. Distinct and replicable genetic risk factors for acute respiratory distress syndrome of pulmonary or extrapulmonary origin. J Med Genet. 2012;49:671–680.
    1. Gibson G. Rare and common variants: twenty arguments. Nat Rev Genet. 2012;13:135–145.
    1. Tennessen JA, Bigham AW, O'Connor TD. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science. 2012;337:64–69.
    1. Posey JE, Harel T, Liu P. Resolution of disease phenotypes resulting from multilocus genomic variation. N Engl J Med. 2017;376:21–31.
    1. Djebali S, Davis CA, Merkel A. Landscape of transcription in human cells. Nature. 2012;489:101–108.
    1. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 2009;10:57–63.
    1. Gibson G, Powell JE, Marigorta UM. Expression quantitative trait locus analysis for translational medicine. Genome Med. 2015;7:60.
    1. Palakshappa JA, Meyer NJ. Which patients with ARDS benefit from lung biopsy? Chest. 2015;148:1073–1082.
    1. Kovach MA, Stringer KA, Bunting R. Microarray analysis identifies IL-1 receptor type 2 as a novel candidate biomarker in patients with acute respiratory distress syndrome. Respir Res. 2015;16:29.
    1. Aggarwal NR, King LS, D'Alessio FR. Diverse macrophage populations mediate acute lung inflammation and resolution. Am J Physiol Lung Cell Mol Physiol. 2014;306:L709–L725.
    1. Kangelaris KN, Prakash A, Liu KD. Increased expression of neutrophil-related genes in patients with early sepsis-induced ARDS. Am J Physiol Lung Cell Mol Physiol. 2015;308:L1102–L1113.
    1. Howrylak JA, Dolinay T, Lucht L. Discovery of the gene signature for acute lung injury in patients with sepsis. Physiol Genomics. 2009;37:133–139.
    1. Rogers AJ, Matthay MA. Applying metabolomics to uncover novel biology in ARDS. Am J Physiol Lung Cell Mol Physiol. 2014;306:L957–L961.
    1. Bhargava M, Becker TL, Viken KJ. Proteomic profiles in acute respiratory distress syndrome differentiates survivors from non-survivors. PLoS One. 2014;9:e109713.
    1. Chen X, Shan Q, Jiang L, Zhu B, Xi X. Quantitative proteomic analysis by iTRAQ for identification of candidate biomarkers in plasma from acute respiratory distress syndrome patients. Biochem Biophys Res Commun. 2013;441:1–6.
    1. Gerszten RE, Accurso F, Bernard GR. Challenges in translating plasma proteomics from bench to bedside: update from the NHLBI Clinical Proteomics Programs. Am J Physiol Lung Cell Mol Physiol. 2008;295:16–22.
    1. Bos LDJ, Weda H, Wang Y. Exhaled breath metabolomics as a noninvasive diagnostic tool for acute respiratory distress syndrome. Eur Respir J. 2014;44:188–197.
    1. Gajic O, Dabbagh O, Park PK. Early identification of patients at risk of acute lung injury: evaluation of lung injury prediction score in a multicenter cohort study. Am J Respir Crit Care Med Medicine. 2011;183:462–470.
    1. Trillo-Alvarez C, Cartin-Ceba R, Kor DJ. Acute lung injury prediction score: derivation and validation in a population-based sample. Eur Respir J. 2011;37:604–609.
    1. Dickson RP, Singer BH, Newstead MW. Enrichment of the lung microbiome with gut bacteria in sepsis and the acute respiratory distress syndrome. Nat Microbiol. 2016;1:16113.
    1. Bernard GR, Artigas A, Brigham KL. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149:818–824.
    1. Schmidt EP, Li G, Li L. The circulating glycosaminoglycan signature of respiratory failure in critically ill adults. J Biol Chem. 2014;289:8194–8202.
    1. Mrozek S, Jabaudon M, Jaber S. Elevated plasma levels of sRAGE are associated with nonfocal CT-based lung imaging in patients with ARDS: a prospective multicenter study. Chest. 2016;150:998–1007.
    1. Calfee CS, Eisner MD, Ware LB. Trauma-associated lung injury differs clinically and biologically from acute lung injury due to other clinical disorders. Crit Care Med. 2007;35:2243–2250.
    1. Constantin JM, Grasso S, Chanques G. Lung morphology predicts response to recruitment maneuver in patients with acute respiratory distress syndrome. Crit Care Med. 2010;38:1108–1117.
    1. Haldar P, Pavord ID, Shaw DE. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178:218–224.
    1. Moore WC, Meyers DA, Wenzel SE. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J Respir Crit Care Med. 2010;181:315–323.
    1. Wong HR, Cvijanovich N, Lin R. Identification of pediatric septic shock subclasses based on genome-wide expression profiling. BMC Med. 2009;7:34.
    1. Wong HR, Cvijanovich NZ, Anas N. Developing a clinically feasible personalized medicine approach to pediatric septic shock. Am J Respir Crit Care Med. 2015;191:309–315.
    1. Quackenbush J. Computational analysis of microarray data. Nat Rev Genet. 2001;2:418–427.
    1. Charrad M, Ghazzali N, Boiteau V, Niknafs A. NbClust: an R package for determining the relevant number of clusters in a data set. J Stat Softw. 2014;61:36.
    1. Churpek MM, Yuen TC, Winslow C, Meltzer DO, Kattan MW, Edelson DP. Multicenter comparison of machine learning methods and conventional regression for predicting clinical deterioration on the wards. Crit Care Med. 2016;44:368–374.
    1. Wong HR, Lindsell CJ, Pettila V. A multi-biomarker-based outcome risk stratification model for adult septic shock. Crit Care Med. 2014;42:781–789.
    1. Brown LM, Calfee CS, Matthay MA, Brower RG, Thompson BT, Checkley W. A simple classification model for hospital mortality in patients with acute lung injury managed with lung protective ventilation. Crit Care Med. 2011;39:2645–2651.
    1. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18:716–725.
    1. Howard R, Rattray M, Prosperi M, Custovic A. Distinguishing asthma phenotypes using machine learning approaches. Curr Allergy Asthma Rep. 2015;15:38.
    1. Reilly JP, Bellamy S, Shashaty MGS. Heterogeneous phenotypes of the acute respiratory distress syndrome after major trauma. Ann Am Thorac Soc. 2014;11:728–736.
    1. Agrawal A, Matthay MA, Kangelaris KN. Plasma angiopoietin-2 predicts the onset of acute lung injury in critically ill patients. Am J Respir Crit Care Med. 2013;187:736–742.
    1. Calfee CS, Gallagher D, Abbott J, Thompson BT, Matthay MA. Plasma angiopoietin-2 in clinical acute lung injury: prognostic and pathogenetic significance. Crit Care Med. 2012;40:1731–1737.
    1. Fremont RD, Koyama T, Calfee CS. Acute lung injury in patients with traumatic injuries: utility of a panel of biomarkers for diagnosis and pathogenesis. J Trauma. 2010;68:1121–1127.
    1. Meyer NJ, Li M, Feng R. ANGPT2 genetic variant is associated with trauma-associated acute lung injury and altered plasma angiopoietin-2 isoform ratio. Am J Respir Crit Care Med. 2011;183:1344–1353.
    1. Westra HJ, Peters MJ, Esko T. Systematic identification of trans-eQTLs as putative drivers of known disease associations. Nat Genet. 2013;45:1238–1243.
    1. Imai K, Keele L, Tingley D. A general approach to causal mediation analysis. Psychol Methods. 2010;15:309–334.
    1. Wei Y, Wang Z, Su L. Platelet count mediates the contribution of a genetic variant in LRRC 16A to ARDS risk. Chest. 2015;147:607–617.
    1. Wei Y, Tejera P, Wang Z. A missense genetic variant in LRRC16A/CAMIL1 improves ARDS survival by attenuating platelet count decline. Am J Respir Crit Care Med. 2016 doi: 10.1164/rccm.201605-0946OC. published online Oct 21.
    1. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37:161–165.
    1. Cohen JC. Emerging LDL therapies: using human genetics to discover new therapeutic targets for plasma lipids. J Clin Lipidol. 2013;7(suppl 3):S1–S5.
    1. Huh D, Leslie DC, Matthews BD. A human disease model of drug toxicity-induced pulmonary edema in a lung-on-a-chip microdevice. Sci Transl Med. 2012;4:159ra147.
    1. Cypel M, Yeung JC, Liu M. Normothermic ex vivo lung perfusion in clinical lung transplantation. N Engl J Med. 2011;364:1431–1440.
    1. Chaney J, Suzuki Y, Cantu E, van Berkel V. Lung donor selection criteria. J Thorac Dis. 2014;6:1032–1038.
    1. McAuley DF, Curley GF, Hamid UI. Clinical grade allogeneic human mesenchymal stem cells restore alveolar fluid clearance in human lungs rejected for transplantation. Am J Physiol Lung Cell Mol Physiol. 2014;306:L809–L815.
    1. Lee JW, Krasnodembskaya A, McKenna DH, Song Y, Abbott J, Matthay MA. Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. Am J Respir Crit Care Med. 2013;187:751–760.
    1. Gores KM, Delsing AS, Kraus SJ. Plasma angiopoietin-2 concentrations are related to impaired lung function, and organ failure in a clinical cohort receiving high dose interleukin-2 therapy. Shock. 2014;42:115–120.
    1. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337:816–821.
    1. Cockrell AS, Yount BL, Scobey T. A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. Nat Microbiol. 2016;2:16226.
    1. Flaherty KT, Robert C, Hersey P. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367:107–114.
    1. Kris MG, Johnson BE, Berry LD. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311:1998–2006.
    1. Ortega HG, Liu MC, Pavord ID. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198–1207.
    1. Freidlin B, Korn EL. Biomarker enrichment strategies: matching trial design to biomarker credentials. Nat Rev Clin Oncol. 2014;11:81–90.
    1. Mehta C, Schafer H, Daniel H, Irle S. Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints. Stat Med. 2014;33:4515–4531.
    1. Geiss GK, Bumgarner RE, Birditt B. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008;26:317–325.
    1. Cuenca AG, Gentile LF, Lopez MC. Development of a genomic metric that can be rapidly used to predict clinical outcome in severely injured trauma patients. Crit Care Med. 2013;41:1175–1185.
    1. Calfee CS, Ware LB, Eisner MD. Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury. Thorax. 2008;63:1083–1089.
    1. Matthay MA, McAuley DF, Ware LB. Clinical trials in ARDS: challenges and opportunities. Lancet Respir Med. 2017;5:524–534.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner